CandlesenseCandlesense
News/Companies/TECX

TECX News

Tectonic Therapeutic to Participate in September Investor Conferences

TECX

WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in three upcoming investor conferences taking place in September 2025.

August 28, 2025Investor Relations
Read more →

Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights

TECX

WATERTOWN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the second quarter ended June 30, 2025, and provided an overview of recent business highlights.

August 7, 2025Earnings
Read more →

Raymond James Reinstates Outperform on Tectonic Therapeutic, Announces $76 Price Target

TECX

June 11, 2025
Read more →

Reported Saturday, Tectonic Therapeutic Presents Full Phase 1b Results For TX45 in PH-HFpEF Showing Sustained Hemodynamic Improvements And Strong Safety Profile

TECX

May 19, 2025
Read more →

Mizuho Maintains Outperform on Tectonic Therapeutic, Raises Price Target to $85

TECX

May 15, 2025
Read more →

Tectonic Therapeutic Q1 EPS $(0.93) Beats $(1.22) Estimate

TECX

May 8, 2025
Read more →

Mizuho Initiates Coverage On Tectonic Therapeutic with Outperform Rating, Announces Price Target of $51

TECX

April 21, 2025
Read more →

Tectonic Therapeutic To Make Late-breaking Oral Presentation At ESC Heart Failure 2025 Congress Highlighting Phase 1B Data For TX45

TECX

April 15, 2025
Read more →

Wells Fargo Maintains Overweight on Tectonic Therapeutic, Lowers Price Target to $101

TECX

March 21, 2025
Read more →

Tectonic Therapeutic Expects Cash And Equivalents Of $141.2M As Of December 2024 And February Private Placement Gross Proceeds Of $185M, To Provide Cash Runway Into Q4'28

TECX

March 20, 2025
Read more →

Tectonic Therapeutic Q4 2024 GAAP EPS $(0.84) Beats $(1.39) Estimate

TECX

March 20, 2025
Read more →

Raymond James Initiates Coverage On Tectonic Therapeutic with Outperform Rating, Announces Price Target of $65

TECX

November 20, 2024
Read more →